Journal of Clinical Microbiology, December 1999, p. 3865-3871, Vol. 37, No. 12
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

III. Medizinische Klink,
Received 22 February 1999/Returned for modification 12 July
1999/Accepted 9 August 1999
The increasing incidence of aspergillosis, a life-threatening
infection in immunocompromised patients, emphasizes the need to improve
the currently limited diagnostic tools. We developed a two-step PCR
assay that specifically amplifies a region of the 18S rRNA gene that is
highly conserved in Aspergillus species. A number of
primers with the least homology to equivalent human or
Candida gene sequences were screened for the pairs that
gave the highest sensitivity and specificity. No cross-reaction with the wide range of fungal and bacterial pathogens so far tested was
observed. This assay allows direct and rapid detection of down to 10 fg
of Aspergillus DNA corresponding to 1 to 5 CFU per ml of
blood. A total of 315 blood and bronchoalveolar lavage samples from 140 subjects, including 93 patients at risk for invasive fungal disease,
were screened. The result was a 100% correlation between positive
histology, culture, or high-resolution computed tomography findings and
PCR results. The test specificity was 89%. Our data point to the
considerable potential clinical value of this simple, specific, rapid,
and inexpensive PCR assay for improving the means of early diagnosis of
systemic aspergillosis in high-risk patients.
*
Corresponding author. Mailing address: III.
Medizinische Klinik, Klinikum Mannheim der Universität
Heidelberg, Wiesbadenerstraße 7-11, D-68305 Mannheim, Germany. Phone:
49-621-383-4115. Fax: 49-621-383-4201. E-mail:
dieter.buchheidt{at}urz.uni-heidelberg.de.
Present address: QIAGEN GmbH, Hilden, Germany.
This article has been cited by other articles:
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|